Dr. Sujuan Ba


Dr. Ba is the President and Chief Operating Officer of the National Foundation for Cancer Research (NFCR) and is recognized as one of the “Top 300 Women Leaders in Global Health” by the Global Health Programme at the Graduate Institute of International and Development Studies. Dr. Ba oversees NFCR’s strategic directions for fundraising, financial planing, scientific direction and partnership development.

Dr. Ba lead the establishment of NFCR’s annual Szent-Györgyi Prize for Progress in Cancer Research, an international prize in recognition of outstanding scientific achievement in the war against cancer. She has served continuously for the past 12 years as co-chair of the Prize Selection Committee which consists of leaders in academic and pharmaceutical sectors. Dr. Ba also founded the Asian Fund for Cancer Research (AFCR), a non-profit organization headquartered in Hong Kong.  As CEO of AFCR, Dr. Ba oversees the fund’s collaborative research initiatives and public prevention programs in Hong Kong, Greater China, and throughout Asia.

Dr. Ba currently serves on the executive committee and Co-Chair of the Patient Focused Research and Advocacy Committee of the GBM-AGILE (Adaptive Global Innovative Learning Environment), a global trial to improve the survival of GBM patients with a global force of over 150 neurosurgeons, neuro-oncologists, pathologists, imagers, basic and clinical neuro scientists, from academic, industry, and government.  She is a member of the Scientific Advisory Board of Medelis, Inc., an oncology CRO located in Fountain Hills, AZ. She also serves on the International Consulting Committee of the China National Research Center for Translational Medicine  in Shanghai.  Dr. Ba is a member of BayHelix, an invitation-only organization of leaders of Chinese origin in the global life sciences and healthcare community based in San Francisco with regional offices in Shanghai and Beijing.

Dr. Ba served on the Organizing Committee for the 2015 Personalized Medicine Conference, a cross-industry, cross-disciplinary panel made up of providers, payers, educators, researchers, and government agency representatives—all committed to personalized medicine.  She served as a Past President (2010-2011) Board of Directors (2006-2013) and is currently a member of the Board of Advisors of the Chinese Biopharmaceutical Association–USA (Rockville, MD). In 2011, she was invited as one of a few business leaders to join Maryland Governor Martin O’Malley’s Trade Mission to Asia and visited China, Korea, and Vietnam with Governor O’Malley.  She also served on the Membership Committee of the International Union against Cancer (Geneva). 

Prior to joining NFCR, Dr. Ba was the Director of Chiral Chemistry and Fine Chemical Consulting Services at Technology Catalysts International (TCI) where she conducted market research, business evaluation, and competitive intelligence for an international clientele of major chemical and pharmaceutical companies. From 1991-1997, she was a Principal Research Chemist and then Project Manager of Technology Development and Research Planning at Arco Chemical Company (ARCO).  Dr. Ba received her B.S. in radiochemistry from Peking University and her Ph.D. in chemistry from the University of Pennsylvania.

John Rompon

Over the course of his 25-year career, John has played a leading role in virtually every aspect of private company activity - structuring transactions as a lawyer, improving operations and developing strategy as a management consultant, starting companies as an entrepreneur, leading management teams as a CEO, and deploying capital as an investor.   In most of these roles, John has focused his efforts on the healthcare and life sciences industries. 

He is the founder and Managing Partner of Marjo Investments LLC, a firm focused on making and managing private company investments alongside family offices.  During the last 6 years, John has lead investments in companies with an aggregate enterprise value of more than $800 million.  Prior to founding Marjo Investments, John was the co-founder and Managing Partner of McNally Capital, a firm dedicated to serving the full range of family office private equity needs.  He was previously a founding member and principal in Hewlett-Packard's global Business Process Outsourcing group and the CEO of Brigade, a General Atlantic Partners portfolio company based in Hyderabad, India.

Earlier in his career, John was a partner with First Consulting Group, a healthcare technology-consulting firm, and a founding partner of SAI, Inc., a healthcare consulting and investment firm, which he and his partners sold to Perot Systems.  John also served as a senior associate with the consulting firm Booz Allen Hamilton and as a lawyer with Latham & Watkins.

John sits on a variety of private company boards and received a B.A. in Economics and History (with honors) from Northwestern University and a J.D. (with highest honors) from Indiana University - Bloomington.

Dr. Santosh Kesari

M.D. Ph.D.

Dr. Kesari is one of the foremost neuro-oncologist in the country.  He is currently the Chair and Director of Neuro-oncology at the John Wayne Cancer Institute, part of the Providence Health System, in Los Angeles.  Dr. Kesari has over 300 peer reviewed journal publications to his credit and leads research efforts in innovative approaches to treating cancer and is highly regarded within the FDA. 


Prior to joining the John Wayne Cancer Institute, Dr. Kesari was Director of Neuro-oncology at UCSD John Moores Cancer Center in San Diego.  Dr. Kesari came to UCSD from Dana-Farber Cancer Institute and Brigham and Women’s Hospital in Boston, where he was assistant professor of neurology at Harvard Medical School since 2007.  Dr. Kesari received his medical degree from the University of Pennsylvania medical school and his PhD in molecular biology from the same institution.

Dr. Vijay Mahant


Dr. Mahant graduated from LUT (UK) and he received his second post-doctorate from UT Health Science Center at Houston/MD Anderson, TX, USA).  Dr. Mahant is a scientist and an entrepreneur with 30 years of experience in immuno- and molecular diagnostics.  He has held executive positions and  he is founder/co-founder of diagnostic companies with diverse experiences  in RD, worked with hospitals /medical institutes such as Mayo Clinic (‘87-’89, “New Generation” ultra-sensitive TSH test  (evaluated and validated by Dr. George Klee , President  of American Thyroid Association ) and worked (2005) with Long Beach Memorial Hospital in setting up a molecular diagnostic lab.


Dr. Mahant has been involved in fund raisings, Initial Public Offerings (IPOs) and he has 25 issued patents and 15 patents pending; he has authored and/or co-authored publications. He has developed more than 35 products  with multi million dollars in revenues. Dr. Mahant has managed intellectual property, including in and out licensing and he has experience in government regulations (FDA and foreign) and provided technical support for many of the products.

Dr. Gregory Ogilvie


Dr. Ogilvie is a world-renowned veterinary oncologist and is board certified in both specialties of internal medicine and oncology by the American College of Veterinary Internal Medicine.  He is a Founding Diplomate of the European College of Veterinary Internal Medicine, Specialty of Oncology.  Dr. Ogilvie is director of the Angel Care Cancer Center at CVS, the president of the Special Care Foundation for Companion Animals, and also serves as the Division Director of Veterinary Oncology at the Univ. of California San Diego, Moores Cancer Center.  Previously, he was a full tenured professor, internist, head of medical oncology and director of the Medical Oncology Research Laboratory, Animal Cancer Center at Colorado State University.  Dr. Ogilvie lectures to thousands of veterinary students, physicians, graduate veterinarians and scientists each year.

Dr. Jonathon D. ("JD") Foster

VMD (PennVet)

Dr. Foster is a veterinary nephrologist and an expert in extracorporeal therapies / apheresis / hemodialysis.  He serves as a staff veterinarian at the Univ. of Pennsylvania School of Veterinary Medicine and is also a Diplomate of the American College of Veterinary Internal Medicine.

Dr. Craig Clifford

DVM, MS, DACVIM (Hope Veterinary Specialists)

Dr. Clifford is a well-renowned veterinary oncologist and serves as the Director of Clinical Studies for Hope Veterinary Specialists. Prior to receiving his DVM from Mississippi State University College of Veterinary Medicine he received an MS degree in Animal Science/Virology from the University of Delaware. He is a Diplomate of the American College of Veterinary Internal Medicine (Oncology).  Dr. Clifford has authored/co-authored over 50 papers and book chapters and he is a frequent lecturer at major veterinary meetings in the U.S. and abroad.  He also serves on the Scientific Advisory Boards for Zoetis, Novartis, and Aratana.




General Inquiries

(657) 202-6388

Media Relations

(657) 202-6040

©2018 Immunicom, Inc. All rights reserved.

  • Black LinkedIn Icon